Taiwanese Pharma Co. Says €142M Award Can't Be Enforced

By Caroline Simson · February 11, 2022, 10:12 PM EST

Taiwanese drug developer PharmaEssentia Corp. is fighting the enforcement of a €142 million ($161.1 million) arbitral award issued to Austrian pharmaceutical company AOP Orphan following an ill-fated deal to develop a...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

AOP Orphan Pharmaceuticals AG v. Pharmaessentia Corporation

Case Number

1:20-cv-12066

Court

Massachusetts

Nature of Suit

Other Statutes: Arbitration

Date Filed

November 19, 2020